Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Descriptive epidemiology of rubella disease and associated virus strains in uganda.

Tushabe P, Bwogi J, Abernathy E, Birungi M, Eliku JP, Seguya R, Bukenya H, Namuwulya P, Kakooza P, Suppiah S, Kabaliisa T, Tibanagwa M, Ampaire I, Kisakye A, Bakainaga A, Byabamazima CR, Icenogle JP, Bakamutumaho B.

J Med Virol. 2019 Oct 9. doi: 10.1002/jmv.25604. [Epub ahead of print]

PMID:
31598987
2.

Successes and challenges for preventing measles, mumps and rubella by vaccination.

Bankamp B, Hickman C, Icenogle JP, Rota PA.

Curr Opin Virol. 2019 Feb;34:110-116. doi: 10.1016/j.coviro.2019.01.002. Epub 2019 Mar 7. Review.

PMID:
30852425
3.

Use of FTA Cards To Transport Throat Swabs and Oral Fluid Samples for Molecular Detection and Genotyping of Measles and Rubella Viruses.

Bankamp B, Sein C, Pukuta Simbu E, Anderson R, Abernathy E, Chen MH, Muyembe Tamfum JJ, Wannemuehler KA, Waku-Kouomou D, Lopareva EN, Icenogle JP, Rota PA, Goodson JL.

J Clin Microbiol. 2019 Apr 26;57(5). pii: e00048-19. doi: 10.1128/JCM.00048-19. Print 2019 May.

PMID:
30814262
4.

Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.

McLean HQ, Fiebelkorn AP, Ogee-Nwankwo A, Hao L, Coleman LA, Adebayo A, Icenogle JP.

Vaccine. 2018 Sep 11;36(38):5732-5737. doi: 10.1016/j.vaccine.2018.08.010. Epub 2018 Aug 11.

PMID:
30107992
5.

Prevalence of Granulomas in Patients With Primary Immunodeficiency Disorders, United States: Data From National Health Care Claims and the US Immunodeficiency Network Registry.

Leung J, Sullivan KE, Perelygina L, Icenogle JP, Fuleihan RL, Lanzieri TM.

J Clin Immunol. 2018 Aug;38(6):717-726. doi: 10.1007/s10875-018-0534-7. Epub 2018 Jul 24.

6.

Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.

Seagle EE, Bednarczyk RA, Hill T, Fiebelkorn AP, Hickman CJ, Icenogle JP, Belongia EA, McLean HQ.

Vaccine. 2018 Feb 1;36(6):818-826. doi: 10.1016/j.vaccine.2017.12.075. Epub 2018 Jan 6.

PMID:
29317117
7.

Assessment of National Public Health and Reference Laboratory, Accra, Ghana, within Framework of Global Health Security.

Ogee-Nwankwo A, Opare D, Boateng G, Nyaku M, Haynes LM, Balajee SA, Conklin L, Icenogle JP, Rota PA, Waku-Kouomou D.

Emerg Infect Dis. 2017 Dec;23(13). doi: 10.3201/eid2313.170372.

8.

Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy.

Alleman MM, Wannemuehler KA, Hao L, Perelygina L, Icenogle JP, Vynnycky E, Fwamba F, Edidi S, Mulumba A, Sidibe K, Reef SE.

Vaccine. 2016 Dec 12;34(51):6502-6511. doi: 10.1016/j.vaccine.2016.10.059. Epub 2016 Nov 17.

9.

Global Measles and Rubella Laboratory Network Support for Elimination Goals, 2010-2015.

Mulders MN, Rota PA, Icenogle JP, Brown KE, Takeda M, Rey GJ, Ben Mamou MC, Dosseh AR, Byabamazima CR, Ahmed HJ, Pattamadilok S, Zhang Y, Gacic-Dobo M, Strebel PM, Goodson JL.

MMWR Morb Mortal Wkly Rep. 2016 May 6;65(17):438-42. doi: 10.15585/mmwr.mm6517a3.

10.

Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial.

Zaman K, Fleming JA, Victor JC, Yunus M, Bari TI, Azim T, Rahman M, Mowla SM, Bellini WJ, McNeal M, Icenogle JP, Lopman B, Parashar U, Cortese MM, Steele AD, Neuzil KM.

J Infect Dis. 2016 Jun 1;213(11):1686-93. doi: 10.1093/infdis/jiw024. Epub 2016 Jan 27.

11.

Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome.

Hyde TB, Sato HK, Hao L, Flannery B, Zheng Q, Wannemuehler K, Ciccone FH, de Sousa Marques H, Weckx LY, Sáfadi MA, de Oliveira Moraes E, Pinhata MM, Olbrich Neto J, Bevilacqua MC, Tabith Junior A, Monteiro TA, Figueiredo CA, Andrus JK, Reef SE, Toscano CM, Castillo-Solorzano C, Icenogle JP; CRS Biomarker Study Group.

J Infect Dis. 2015 Jul 1;212(1):57-66. doi: 10.1093/infdis/jiu604. Epub 2014 Oct 31.

12.

Congenital rubella syndrome in child of woman without known risk factors, New Jersey, USA.

Pitts SI, Wallace GS, Montana B, Handschur EF, Meislich D, Sampson AC, Canuso S, Horner J, Barskey AE, Abernathy ES, Icenogle JP.

Emerg Infect Dis. 2014 Feb;20(2):307-9. doi: 10.3201/eid2002.131233.

13.

High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers.

Lambert ND, Pankratz VS, Larrabee BR, Ogee-Nwankwo A, Chen MH, Icenogle JP, Poland GA.

Clin Vaccine Immunol. 2014 Mar;21(3):340-6. doi: 10.1128/CVI.00681-13. Epub 2014 Jan 3.

14.

Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience.

Papania MJ, Wallace GS, Rota PA, Icenogle JP, Fiebelkorn AP, Armstrong GL, Reef SE, Redd SB, Abernathy ES, Barskey AE, Hao L, McLean HQ, Rota JS, Bellini WJ, Seward JF.

JAMA Pediatr. 2014 Feb;168(2):148-55. doi: 10.1001/jamapediatrics.2013.4342.

PMID:
24311021
15.

Genotyping of rubella virus RNA in sera and dried blood spots collected during routine surveillance and in archival sera.

Zheng Q, Abernathy ES, Sun H, Zhu Z, de Filippis A, Akoua-Koffi C, Ahmed H, Morris-Glasgow V, Quist-Therson M, Icenogle JP.

J Virol Methods. 2013 Feb;187(2):284-7. doi: 10.1016/j.jviromet.2012.11.023. Epub 2012 Nov 29.

PMID:
23201287
16.

Virologic surveillance for wild-type rubella viruses in the Americas.

Icenogle JP, Siqueira MM, Abernathy ES, Lemos XR, Fasce RA, Torres G, Reef SE.

J Infect Dis. 2011 Sep 1;204 Suppl 2:S647-51. doi: 10.1093/infdis/jir431.

PMID:
21954261
17.

Evidence used to support the achievement and maintenance of elimination of rubella and congenital rubella syndrome in the United States.

Reef SE, Redd SB, Abernathy E, Kutty P, Icenogle JP.

J Infect Dis. 2011 Sep 1;204 Suppl 2:S593-7. doi: 10.1093/infdis/jir420.

PMID:
21954252
18.

Status of global virologic surveillance for rubella viruses.

Abernathy ES, Hübschen JM, Muller CP, Jin L, Brown D, Komase K, Mori Y, Xu W, Zhu Z, Siqueira MM, Shulga S, Tikhonova N, Pattamadilok S, Incomserb P, Smit SB, Akoua-Koffi C, Bwogi J, Lim WW, Woo GK, Triki H, Jee Y, Mulders MN, de Filippis AM, Ahmed H, Ramamurty N, Featherstone D, Icenogle JP.

J Infect Dis. 2011 Jul;204 Suppl 1:S524-32. doi: 10.1093/infdis/jir099.

PMID:
21666209
19.

An indirect immunocolorimetric assay to detect rubella virus infected cells.

Chen MH, Zhu Z, Zhang Y, Favors S, Xu WB, Featherstone DA, Icenogle JP.

J Virol Methods. 2007 Dec;146(1-2):414-8. Epub 2007 Oct 24.

PMID:
17919742
20.

Genetic analysis of rubella viruses found in the United States between 1966 and 2004: evidence that indigenous rubella viruses have been eliminated.

Icenogle JP, Frey TK, Abernathy E, Reef SE, Schnurr D, Stewart JA.

Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S133-40.

PMID:
16998772
21.

The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998-2004: the evidence for absence of endemic transmission.

Reef SE, Redd SB, Abernathy E, Zimmerman L, Icenogle JP.

Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S126-32.

PMID:
16998771
22.

Development of a rubella vaccination strategy: contribution of a rubella susceptibility study of women of childbearing age in Kyrgyzstan, 2001.

Malakmadze N, Zimmerman LA, Uzicanin A, Shteinke L, Caceres VM, Kasymbekova K, Sozina I, Glasser JW, Joldubaeva M, Aidyralieva C, Icenogle JP, Strebel PM, Reef SE.

Clin Infect Dis. 2004 Jun 15;38(12):1780-3. Epub 2004 May 17.

PMID:
15227627
23.
24.

Characterization of a novel coronavirus associated with severe acute respiratory syndrome.

Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Peñaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Günther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ.

Science. 2003 May 30;300(5624):1394-9. Epub 2003 May 1.

25.

Identifying risk factors for rubella susceptibility in a population at risk in the United States.

Danovaro-Holliday MC, Gordon ER, Woernle C, Higginbotham GH, Judy RH, Icenogle JP, Reef SE.

Am J Public Health. 2003 Feb;93(2):289-91. No abstract available.

26.

A large rubella outbreak with spread from the workplace to the community.

Danovaro-Holliday MC, LeBaron CW, Allensworth C, Raymond R, Borden TG, Murray AB, Icenogle JP, Reef SE.

JAMA. 2000 Dec 6;284(21):2733-9.

PMID:
11105178
27.

Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type.

Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP.

J Clin Microbiol. 1999 Apr;37(4):1030-4.

28.

A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: differences among racial/ethnic groups.

Tortolero-Luna G, Mitchell MF, Swan DC, Tucker RA, Wideroff L, Icenogle JP.

Cad Saude Publica. 1998;14 Suppl 3:149-59.

PMID:
9819473
29.

Expression of ras, c-myc, and p53 proteins in cervical intraepithelial neoplasia.

Slagle BL, Kaufman RH, Reeves WC, Icenogle JP.

Cancer. 1998 Oct 1;83(7):1401-8.

PMID:
9762942
30.

Human papillomavirus and disease status following therapy for cervical cancer.

Unger ER, Vernon SD, Nisenbaum R, Thoms WW, Spann C, Miller DL, Lee DR, Horowitz IR, Icenogle JP, Reeves WC.

Clin Infect Dis. 1998 Feb;26(2):373-8.

PMID:
9502457
31.

A sensitive, type-specific, fluorogenic probe assay for detection of human papillomavirus DNA.

Swan DC, Tucker RA, Holloway BP, Icenogle JP.

J Clin Microbiol. 1997 Apr;35(4):886-91.

32.

Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31.

Icenogle JP, Clancy KA, Lin SY.

Virology. 1995 Dec 20;214(2):664-9.

33.

Cervical cancer survival in a high risk urban population.

Thoms WW, Unger ER, Johnson PR, Spann CO, Hunter SH, Smith R, Horowitz IR, Icenogle JP, Vernon SD, Reeves WC.

Cancer. 1995 Dec 15;76(12):2518-23. Review.

PMID:
8625079
34.

Divergent human papillomavirus type 16 variants are serologically cross-reactive.

Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, St Louis ME, Han C, Svare EI, Kjaer SK, Lowy DR, Schiller JT.

J Infect Dis. 1995 Dec;172(6):1584-7.

PMID:
7594721
35.

Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer.

Unger ER, Vernon SD, Thoms WW, Nisenbaum R, Spann CO, Horowitz IR, Icenogle JP, Reeves WC.

J Infect Dis. 1995 Nov;172(5):1184-90.

PMID:
7594652
36.

Risk factors for genital papillomavirus infection in populations at high and low risk for cervical cancer.

Reeves WC, Gary HE Jr, Johnson PR, Icenogle JP, Brenes MM, de Britton RM, Dobbins JG, Schmid DS.

J Infect Dis. 1994 Oct;170(4):753-8.

PMID:
7930714
37.
38.

A longitudinal study of human papillomavirus DNA detection in human immunodeficiency virus type 1-seropositive and -seronegative women.

Vernon SD, Reeves WC, Clancy KA, Laga M, St Louis M, Gary HE Jr, Ryder RW, Manoka AT, Icenogle JP.

J Infect Dis. 1994 May;169(5):1108-12.

PMID:
8169402
39.

Cellular proteins involved in papillomavirus-induced transformation.

Swan DC, Vernon SD, Icenogle JP.

Arch Virol. 1994;138(1-2):105-15. Review.

PMID:
7980001
40.

The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations.

Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster W, Mavromara-Nazos P, et al.

J Virol. 1993 Nov;67(11):6413-23.

41.
42.

Genital types of papillomavirus in children of women with HIV-1 infection in Kinshasa, Zaire.

St Louis ME, Icenogle JP, Manzila T, Kamenga M, Ryder RW, Heyward WL, Reeves WC.

Int J Cancer. 1993 May 8;54(2):181-4.

PMID:
8387461
43.

The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription.

Vernon SD, Hart CE, Reeves WC, Icenogle JP.

Virus Res. 1993 Feb;27(2):133-45.

PMID:
8384765
44.

Human papillomavirus, human immunodeficiency virus, and cervical cancer: newly recognized associations?

Vernon SD, Icenogle JP, Johnson PR, Reeves WC.

Infect Agents Dis. 1992 Dec;1(6):319-24. Review.

PMID:
1344670
45.
46.

Three-dimensional structure of Theiler virus.

Grant RA, Filman DJ, Fujinami RS, Icenogle JP, Hogle JM.

Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2061-5.

47.

Genital papillomavirus infection and cervical dysplasia--opportunistic complications of HIV infection.

Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, Vermund SH, Heyward WL, Nelson A, Reeves WC.

Int J Cancer. 1992 Jan 2;50(1):45-8.

PMID:
1309459
48.

Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16.

Icenogle JP, Sathya P, Miller DL, Tucker RA, Rawls WE.

Virology. 1991 Sep;184(1):101-7.

PMID:
1651585
49.

Modulation of humoral response to a 12-amino-acid site on the poliovirus virion.

Icenogle JP, Minor PD, Ferguson M, Hogle JM.

J Virol. 1986 Oct;60(1):297-301.

50.

Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Minor PD, Ferguson M, Evans DM, Almond JW, Icenogle JP.

J Gen Virol. 1986 Jul;67 ( Pt 7):1283-91.

PMID:
2425046

Supplemental Content

Loading ...
Support Center